CNTA CENTESSA PHARMACEUTICALS PLC Company Mergers 8-K Filing 2025 - License Agreement On February 14, 2025, Centessa Pharmaceuticals entered into a License Agreement with Genmab, granting them exclusive rights to use Centessa's LockBody platform for research on up to three targets, with Centessa receiving $15 million upfront and potential future payments totaling approximately $230 million.Get access to all SEC 8-K filings of the CENTESSA PHARMACEUTICALS PLC